Immunogenicity assessment remains a critical component in the development of vaccines and biotherapeutics, with distinct analytical strategies and regulatory expectations across modalities.
This on-demand webinar explores the evolving landscape of immunogenicity bioanalysis, highlighting the key differences between vaccine and biologics workflows, and the growing importance of robust ADA (anti-drug antibody) strategies.
By watching this webinar, you will gain insights into:
Key factors influencing immunogenicity (product, patient, study design)
Challenges in ADA detection and characterisation
Assay development complexities and sensitivity considerations
Best practices for data interpretation in immunogenicity studies
Real‑world case studies from Aragen Biosafety Solutions
Emerging opportunities in immunogenicity bioanalysis driven by biologics pipelines
Dr. Kedar Purnapatre, PhD
Director – Bioanalytical Operations, Aragen Life Sciences
